Sitagliptin Results in a Decrease of Truncated Apolipoprotein C1

Diabetes Therapy

Volumn 6, Issue 3, 2015, Pages 395-401

  Skinner, Nicole E B ^a   Wroblewski, Matthew S ^b   Kirihara, Julie A ^b   Nelsestuen, Gary L ^b   Seaquist, Elizabeth R ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Apolipoprotein C1; Mass spectrometry; Sitagliptin

Indexed keywords

APOLIPOPROTEIN C1; HEMOGLOBIN A1C; ISOPROTEIN; SITAGLIPTIN;

ADULT; AMINO ACID SEQUENCE; ARTICLE; BLOOD SAMPLING; DIABETES MELLITUS; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; KINETIC PARAMETERS; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN POLYMORPHISM;

EID: 84942323622     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-015-0123-1     Document Type: Article

References (29)

1. Poensgen J. Apolipoprotein C-1 inhibits the hydrolysis by phospholipase A2 of phospholipids in liposomes and cell membranes. Biochim Biophys Acta. 1990;1042(2):188–92.
2. Berbee JF, van der Hoogt CC, Sundararaman D, Havekes LM, Rensen PC. Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL. J Lipid Res. 2005;46(2):297–306.
3. Conde-Knape K, Bensadoun A, Sobel JH, Cohn JS, Shachter NS. Overexpression of apoC-I in apoE-null mice: severe hypertriglyceridemia due to inhibition of hepatic lipase. J Lipid Res. 2002;43(12):2136–45.
4. Sehayek E, Eisenberg S. Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway. J Biol Chem. 1991;266(27):18259–67.
5. Weisgraber KH, Mahley RW, Kowal RC, Herz J, Goldstein JL, Brown MS. Apolipoprotein C-I modulates the interaction of apolipoprotein E with beta-migrating very low density lipoproteins (beta-VLDL) and inhibits binding of beta-VLDL to low density lipoprotein receptor-related protein. J Biol Chem. 1990;265(36):22453–9.
6. Kushwaha RS, Hasan SQ, McGill HC Jr, Getz GS, Dunham RG, Kanda P. Characterization of cholesteryl ester transfer protein inhibitor from plasma of baboons (Papio sp.). J Lipid Res. 1993;34(8):1285–97.
7. Muurling M, van den Hoek AM, Mensink RP, Pijl H, Romijn JA, Havekes LM, Voshol PJ. Overexpression of APOC1 in obob mice leads to hepatic steatosis and severe hepatic insulin resistance. J Lipid Res. 2004;45(1):9–16.
8. Anuurad E, Yamasaki M, Shachter N, Pearson TA, Berglund L. ApoE and ApoC-I polymorphisms: association of genotype with cardiovascular disease phenotype in African Americans. J Lipid Res. 2009;50(7):1472–8.
9. Gao L, Gabriel C, Lavoie T, Ye SQ. An improved RSP method to detect HpaI polymorphism in the apolipoprotein C-1 gene promoter. BMC Med Genet. 2002;3:13.
10. Retz W, Thome J, Durany N, Harsanyi A, Retz-Junginger P, Kornhuber J, Riederer P, Rosler M. Potential genetic markers of sporadic Alzheimer’s dementia. Psychiatr Genet. 2001;11(3):115–22.
11. Shachter NS, Rabinowitz D, Stohl S, Conde-Knape K, Cohn JS, Deckelbaum RJ, Berglund L, Shea S. The common insertional polymorphism in the APOC1 promoter is associated with serum apolipoprotein C-I levels in Hispanic children. Atherosclerosis. 2005;179(2):387–93.
12. Smit M, van der Kooij-Meijs E, Woudt LP, Havekes LM, Frants RR. Exact localization of the familial dysbetalipoproteinemia associated HpaI restriction site in the promoter region of the APOC1 gene. Biochem Biophys Res Commun. 1988;152(3):1282–8.
13. Nelsestuen GL, Zhang Y, Martinez MB, Key NS, Jilma B, Verneris M, Sinaiko A, Kasthuri RS. Plasma protein profiling: unique and stable features of individuals. Proteomics. 2005;5(15):4012–24.
14. Bondarenko PV, Cockrill SL, Watkins LK, Cruzado ID, Macfarlane RD. Mass spectral study of polymorphism of the apolipoproteins of very low density lipoprotein. J Lipid Res. 1999;40(3):543–55.
15. Rozek A, Sparrow JT, Weisgraber KH, Cushley RJ. Sequence-specific 1H NMR resonance assignments and secondary structure of human apolipoprotein C-I in the presence of sodium dodecyl sulfate. Biochem Cell Biol. 1998;76(2–3):267–75.
16. Wroblewski MS, Wilson-Grady JT, Martinez MB, Kasthuri RS, McMillan KR, Flood-Urdangarin C, Nelsestuen GL. A functional polymorphism of apolipoprotein C1 detected by mass spectrometry. FEBS J. 2006;273(20):4707–15.
17. Lahiry P, Cao H, Ban MR, Pollex RL, Mamakeesick M, Zinman B, Harris SB, Hanley AJ, Huff MW, Connelly PW, Hegele RA. APOC1 T45S polymorphism is associated with reduced obesity indices and lower plasma concentrations of leptin and apolipoprotein C-I in aboriginal Canadians. J Lipid Res. 2010;51(4):843–8.
18. Kasthuri RS, McMillan KR, Flood-Urdangarin C, Harvey SB, Wilson-Grady JT, Nelsestuen GL. Correlation of a T45S variant of apolipoprotein C1 with elevated BMI in persons of American Indian and Mexican ancestries. Int J Obes (Lond). 2007;31(8):1334–6.
19. Shi J, Zhang S, Ma C, Liu X, Li T, Tang M, Han H, Guo Y, Zhao J, Zheng K, Kong X, Zhang K, Su Z, Zhao Z. Association between apolipoprotein CI HpaI polymorphism and sporadic Alzheimer’s disease in Chinese. Acta Neurol Scand. 2004;109(2):140–5.
20. Mentlein R. Dipeptidyl-peptidase IV (CD26)—role in the inactivation of regulatory peptides. Regul Pept. 1999;85(1):9–24.
21. Lambeir AM, Proost P, Durinx C, Bal G, Senten K, Augustyns K, Scharpe S, Van Damme J, De Meester I. Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family. J Biol Chem. 2001;276(32):29839–45.
22. Lambeir AM, Proost P, Scharpe S, De Meester I. A kinetic study of glucagon-like peptide-1 and glucagon-like peptide-2 truncation by dipeptidyl peptidase IV, in vitro. Biochem Pharmacol. 2002;64(12):1753–6.
23. Chen X. Biochemical properties of recombinant prolyl dipeptidases DPP-IV and DPP8. Adv Exp Med Biol. 2006;575:27–32.
24. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2006;49(11):2564–71.
25. Nelsestuen GL, Harvey SB, Zhang Y, Kasthuri RS, Sinaiko AR, Ely EW, Bernard GR, Homoncik M, Jilma B. Top-down proteomic analysis by MALDI-TOF profiling: concentration-independent biomarkers. Proteomics Clin Appl. 2008;2(2):158–66.
26. Puppione DL, Yam LM, Bassilian S, Souda P, Castellani LW, Schumaker VN, Whitelegge JP. Mass spectral analysis of the apolipoproteins on mouse high density lipoproteins. Detection of post-translational modifications. Biochim Biophys Acta. 2006;1764(8):1363–71.
27. Puppione DL, Bassilian S, Souda P, MacDonald MH, Halgand F, Whitelegge JP. Mass spectral analysis of the apolipoproteins on dog (Canis lupus familiaris) high density lipoproteins. Detection of apolipoprotein A-II. Comp Biochem Physiol Part D Genomics Proteomics. 2008;3(4):290–6.
28. Cohn JS, Batal R, Tremblay M, Jacques H, Veilleux L, Rodriguez C, Mamer O, Davignon J. Plasma turnover of HDL apoC-I, apoC-III, and apoE in humans: in vivo evidence for a link between HDL apoC-III and apoA-I metabolism. J Lipid Res. 2003;44(10):1976–83.
29. Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M, Snyder K, Hilliard D, Tanen M, Tanaka W, Wang AQ, Zeng W, Musson D, Winchell G, Davies MJ, Ramael S, Gottesdiener KM, Wagner JA. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther. 2005;78(6):675–88.